CEO and President Quantum Medicine USA
Time : 10:00-10:40
Galina Migalko, M.D., N.M.D. brings more than 30 years of excellence in non-invasive Diagnostic Medical Imaging. After graduating with her M.D. from Uzghorod Medical University, Ukraine in 1988, Dr. Magalko worked for years in wellness clinics and diagnostic medical centers as practitioner and administrator. She has pioneered and developed a revolutionary Full Body Comprehensive Medical Diagnostic Non-Invasive, Painless, Non-Radioactive Scan which includes a Full Body Medical Bio-Electric Scan, Interstatial Metabolic pH Testing, detailed medical reports and consultation to evaluate all physiological, anatomical and functional information about all tissues, glands and organ systems.
Dr. Migalko is the world’s leader in non-invasive, non-radioactive diagnosis treatment and early detection of cancer, heart disease, diabetes, metabolic acidosis, circulatory and lymphatic issues, infertility, and other preventable and treatable health challenges.
Dr. Migalko relocated to the United States in 1998. In 2011 she received her NMD from the University of Science, Arts & Technology in Montserrat, West Indies, and as CEO and President, founded Universal Medical Imaging Group that centers on the importance and principles of wellness and early detection.
Currently she is working on her dissertation in Quantum Medicine showing the benefits of combining the best from the conventional Western medicine with complementary and alternative diagnostic services and therapies.
While a growing body of research now suggests that x-ray mammography is causing more harm than good in the millions of women who subject themselves to breast screenings, annually, without knowledge of their true health risks, the primary focus has been on the harms associated with over-diagnosis and over-treatment, and not the radiobiological dangers of the procedure itself.
In 2006, a paper published in the British Journal of Radiobiology, titled “Enhanced biological effectiveness of low energy X-rays and implications for the UK breast screening programme,” revealed the type of radiation used in x-ray-based breast screenings is much more carcinogenic than previously believed.
Recent radiobiological studies have provided compelling evidence that the low energy X-rays as used in mammography are approximately four times – but possibly as much as six times – more effective in causing mutational damage than higher energy X-rays. Since current radiation risk estimates are based on the effects of high energy gamma radiation, this implies that the risks of radiation-induced breast cancers for mammography X-rays are underestimated by the same factor.